Medical Science Monitor Basic Research has been selected for the ESCI - Emerging Sources Citation Index (Thomson Reuters, Web of Science, ISI), launching in November 2015 as a new edition of the Web of Science.read more
Medical Science Monitor Basic Research has been selected for the ESCI - Emerging Sources Citation Index (Thomson Reuters, Web of Science, ISI), launching in November 2015 as a new edition of the Web of Science.
Glucose Transporter-1 (GLUT-1) Expression is Associated with Tumor Size and Poor Prognosis in Locally Advanced Gastric Cancer
Chenqing Yin, Bin Gao, Ju Yang, Jingbo Wu
(Department of General Surgery, The Fifth People’s Hospital of Shanghai, Fudan University, Shanghai, China (mainland))
Med Sci Monit Basic Res 2020; 26:e920778
The clinicopathological parameters associated with glucose transporter-1 (GLUT-1) expression in advanced gastric cancer are still controversial. This study aimed to determine the clinicopathological parameters and prognosis associated with GLUT-1 expression in advanced gastric cancer.
MATERIAL AND METHODS: The GLUT-1 expression level of 234 consecutive gastric cancer samples was detected by immunohistochemical staining and evaluated by semiquantitative analysis. The clinicopathological data and expression level of GLUT-1 of enrolled patients were retrospectively analyzed with univariate and multivariate analyses.
RESULTS: Tumor size, depth of invasion, and Lauren classification were independent factors related to GLUT-1 expression (P<0.05). Within advanced gastric cancer, tumor size and Lauren type were independent factors associated with GLUT-1 (P=0.011, P<0.001, respectively). The mean survival time of GLUT-1-positive patients with stage M0 advanced gastric cancer who had undergone radical gastrectomy was shorter than that of GLUT-1-negative patients (61.26±6.12 versus 80.88±7.38, P=0.044). GLUT-1 was an independent prognosis factor in locally advanced gastric cancer patients who had undergone radical gastrectomy (hazard ratio [HR] 1.769, P=0.046). The mean survival time of adjuvant chemotherapy was significantly better than no adjuvant chemotherapy in the GLUT-1-positive group (71.10±6.88 versus 24.65±8.69, P<0.001) and in the GLUT-1 negative group (87.48±7.99 versus 49.39±11.71, P<0.001).
CONCLUSIONS: Tumor size and Lauren type independently affected GLUT-1 expression in advanced gastric cancer. GLUT-1 was not only related to poor prognosis but also predicted to be a metabolic biomarker for intestinal type in locally advanced gastric cancer. The relationship among GLUT-1, hepatic metastasis and chemotherapy regimens, and mechanism of chemotherapy responses related to GLUT-1 should be further investigated.
Keywords: Chemotherapy, Adjuvant, Glucose Transporter Type 1, Prognosis, Stomach Neoplasms